Evaluación de la quimioprofilaxis con zidovudine a la mujer embarazada VIH(+) y su hijo

Quian Rivero, Jorge W; Picón Manduco, Teresa B; Rodríguez Tanoni, Ma. Irene; Gutiérrez Rodriguez, Stella I; González Banfi, Alicia C; Nin Márquez, Margarita M; Galazka Cukier, Jeanette R; Martín Nemer, Jacqueline; Galeano Gubitosi, Virginia C; Cafferata, Ma. Luisa; Russi Cahill, José Carlos; Pérez, Ma. Teresa; Ruchansky, Dora.
Arch. pediatr. Urug ; 72(1): 72-6, 2001.
Artículo en Español | BVSNACUY | ID: bnu-10969

Documentos relacionados

  1. Third-Generation Transdermal Delivery Systems Containing Zidovudine: Effect of the Combination of Different Chemical Enhancers and a Microemulsion System.
  2. Safety of zidovudine/lamivudine scored tablets in children with HIV infection in Europe and Thailand.
  3. The Use of Zidovudine Pharmacophore in Multi-Target-Directed Ligands for AIDS Therapy.
  4. Clinical Trials That Have Changed Clinical Practice and Care of Pregnant People With HIV.
  5. Zidovudine (azidothymidine, AZT) unexpressed clinical potential against multidrug-resistant Gram-negative isolates.
  6. Sustainable Protocol for the Synthesis of 2',3'-Dideoxynucleoside and 2',3'-Didehydro-2',3'-dideoxynucleoside Derivatives.
  7. Fevipiprant (QAW039) does not affect the pharmacokinetics of zidovudine, its glucuronide, and penicillin G via inhibition of UGT2B7 and/or OAT3.
  8. Assessment of complex genomic alterations induced by AZT, 3TC, and the combination AZT +3TC.
  9. Anti-retroviral treatment with zidovudine alters pyrimidine metabolism, reduces translation, and extends healthy longevity via ATF-4.
  10. The cascade of care to prevent mother-to-child transmission in Rio de Janeiro, Brazil, 1996-2013: improving but still some way to go.